The best indicator for Quest Diagnostics (DGX)
We backtested 20 indicators across daily, weekly and hourly charts on real Quest Diagnostics (DGX) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Stochastic
On the weekly chart, this is the strongest risk-adjusted edge we found for Quest Diagnostics (DGX) over ~29.6 years — trailing buy-and-hold by 5.0% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Stochastic ✓ | Weekly | 10.8% | 0.76 | -27.4% | 75.0% | 32 | -5.0% |
| 2 | Williams %R ✓ | Weekly | 9.9% | 0.68 | -34.7% | 74.4% | 43 | -5.9% |
| 3 | CCI ✓ | Weekly | 8.4% | 0.63 | -27.5% | 78.1% | 32 | -7.4% |
| 4 | WaveTrend (8/6/4) ✓ | Weekly | 7.5% | 0.56 | -27.5% | 95.2% | 21 | -8.2% |
| 5 | EMA-10 Trend ✓ | Weekly | 8.6% | 0.49 | -36.0% | 46.2% | 132 | -7.2% |
| 6 | Rate of Change ✓ | Daily | 8.0% | 0.47 | -46.3% | 44.5% | 458 | -8.1% |
| 7 | Heikin-Ashi Trend ✓ | Weekly | 7.8% | 0.46 | -30.2% | 50.6% | 267 | -8.0% |
| 8 | Holy Grail Confluence | Daily | 5.9% | 0.45 | -44.9% | 75.6% | 41 | -10.2% |
| 9 | CCI ✓ | Daily | 6.4% | 0.44 | -48.8% | 69.4% | 147 | -9.7% |
| 10 | Bollinger Mean-Reversion ✓ | Weekly | 5.3% | 0.43 | -36.4% | 86.4% | 22 | -10.4% |
| 11 | Money Flow Index ✓ | Daily | 5.5% | 0.4 | -47.8% | 79.3% | 29 | -10.6% |
| 12 | Donchian Midline ✓ | Weekly | 6.5% | 0.4 | -44.7% | 49.4% | 85 | -9.2% |
| 13 | WaveTrend (8/6/4) ✓ | Daily | 5.9% | 0.39 | -45.4% | 70.8% | 106 | -10.2% |
| 14 | MACD | Weekly | 5.9% | 0.39 | -50.3% | 49.3% | 67 | -9.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Quest Diagnostics (DGX), Stochastic on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.